NGS allows the testing of all types of variants including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes and translocations.
The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.
Market Analysis and Insights: Global Clinical Oncology Next Generation Sequencing (NGS) Market
The global Clinical Oncology Next Generation Sequencing (NGS) market size is projected to reach US$ 782.8 million by 2026, from US$ 704.7 million in 2020, at a CAGR of 10.6%% during 2021-2026.
Global Clinical Oncology Next Generation Sequencing (NGS) Scope and Market Size
Clinical Oncology Next Generation Sequencing (NGS) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Clinical Oncology Next Generation Sequencing (NGS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics
Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Type
NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis
Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Application
Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities
The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.
Market Analysis and Insights: Global Clinical Oncology Next Generation Sequencing (NGS) Market
The global Clinical Oncology Next Generation Sequencing (NGS) market size is projected to reach US$ 782.8 million by 2026, from US$ 704.7 million in 2020, at a CAGR of 10.6%% during 2021-2026.
Global Clinical Oncology Next Generation Sequencing (NGS) Scope and Market Size
Clinical Oncology Next Generation Sequencing (NGS) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Clinical Oncology Next Generation Sequencing (NGS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics
Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Type
NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis
Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Application
Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Clinical Oncology Next Generation Sequencing (NGS) Revenue
1.4 Market by Type
1.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 NGS Pre-Sequencing
1.4.3 Sequencing
1.4.4 NGS Data Analysis
1.4.5 Primary, Secondary & Tertiary Data Analysis
1.5 Market by Application
1.5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application: 2020 VS 2026
1.5.2 Academic & Clinical Research
1.5.3 Hospitals & Clinics
1.5.4 Pharma & Biotech Entities
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Perspective (2015-2026)
2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Growth Trends by Regions
2.2.1 Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Historic Market Share by Regions (2015-2020)
2.2.3 Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Clinical Oncology Next Generation Sequencing (NGS) Market Growth Strategy
2.3.6 Primary Interviews with Key Clinical Oncology Next Generation Sequencing (NGS) Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Market Size
3.1.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue (2015-2020)
3.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Players (2015-2020)
3.1.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio
3.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2019
3.3 Clinical Oncology Next Generation Sequencing (NGS) Key Players Head office and Area Served
3.4 Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
3.5 Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Type (2015-2020)
4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
6.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in North America (2019-2020)
6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
6.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
7 Europe
7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
7.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Europe (2019-2020)
7.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
7.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
8 China
8.1 China Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
8.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in China (2019-2020)
8.3 China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
8.4 China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
9 Japan
9.1 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
9.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Japan (2019-2020)
9.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
9.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
10.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
10.4 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
11 India
11.1 India Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
11.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in India (2019-2020)
11.3 India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
11.4 India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
12.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Central & South America (2019-2020)
12.3 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
12.4 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Illumina
13.1.1 Illumina Company Details
13.1.2 Illumina Business Overview
13.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.1.4 Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020))
13.1.5 Illumina Recent Development
13.2 Roche
13.2.1 Roche Company Details
13.2.2 Roche Business Overview
13.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.2.4 Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.2.5 Roche Recent Development
13.3 Agilent Technologies
13.3.1 Agilent Technologies Company Details
13.3.2 Agilent Technologies Business Overview
13.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.3.4 Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.3.5 Agilent Technologies Recent Development
13.4 Knome
13.4.1 Knome Company Details
13.4.2 Knome Business Overview
13.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.4.4 Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.4.5 Knome Recent Development
13.5 Genomatix Software
13.5.1 Genomatix Software Company Details
13.5.2 Genomatix Software Business Overview
13.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.5.4 Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.5.5 Genomatix Software Recent Development
13.6 GATC Biotech
13.6.1 GATC Biotech Company Details
13.6.2 GATC Biotech Business Overview
13.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.6.4 GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.6.5 GATC Biotech Recent Development
13.7 Oxford Nanopore Technologies
13.7.1 Oxford Nanopore Technologies Company Details
13.7.2 Oxford Nanopore Technologies Business Overview
13.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.7.4 Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.7.5 Oxford Nanopore Technologies Recent Development
13.8 Macrogen
13.8.1 Macrogen Company Details
13.8.2 Macrogen Business Overview
13.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.8.4 Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.8.5 Macrogen Recent Development
13.9 Life Technologies
13.9.1 Life Technologies Company Details
13.9.2 Life Technologies Business Overview
13.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.9.4 Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.9.5 Life Technologies Recent Development
13.10 DNASTAR
13.10.1 DNASTAR Company Details
13.10.2 DNASTAR Business Overview
13.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.10.4 DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.10.5 DNASTAR Recent Development
13.11 Exosome Diagnostics
10.11.1 Exosome Diagnostics Company Details
10.11.2 Exosome Diagnostics Business Overview
10.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.11.4 Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.11.5 Exosome Diagnostics Recent Development
13.12 Biomatters
10.12.1 Biomatters Company Details
10.12.2 Biomatters Business Overview
10.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.12.4 Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.12.5 Biomatters Recent Development
13.13 CLC Bio
10.13.1 CLC Bio Company Details
10.13.2 CLC Bio Business Overview
10.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.13.4 CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.13.5 CLC Bio Recent Development
13.14 BGI
10.14.1 BGI Company Details
10.14.2 BGI Business Overview
10.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.14.4 BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.14.5 BGI Recent Development
13.15 Qiagen
10.15.1 Qiagen Company Details
10.15.2 Qiagen Business Overview
10.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.15.4 Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.15.5 Qiagen Recent Development
13.16 Perkin Elmer
10.16.1 Perkin Elmer Company Details
10.16.2 Perkin Elmer Business Overview
10.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.16.4 Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.16.5 Perkin Elmer Recent Development
13.17 Pacific Bioscience
10.17.1 Pacific Bioscience Company Details
10.17.2 Pacific Bioscience Business Overview
10.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.17.4 Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.17.5 Pacific Bioscience Recent Development
13.18 Partek
10.18.1 Partek Company Details
10.18.2 Partek Business Overview
10.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.18.4 Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.18.5 Partek Recent Development
13.19 GnuBIO
10.19.1 GnuBIO Company Details
10.19.2 GnuBIO Business Overview
10.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.19.4 GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.19.5 GnuBIO Recent Development
13.20 Foundation Medicine
10.20.1 Foundation Medicine Company Details
10.20.2 Foundation Medicine Business Overview
10.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.20.4 Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.20.5 Foundation Medicine Recent Development
13.21 Paradigm
10.21.1 Paradigm Company Details
10.21.2 Paradigm Business Overview
10.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.21.4 Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.21.5 Paradigm Recent Development
13.22 Caris Life Sciences
10.22.1 Caris Life Sciences Company Details
10.22.2 Caris Life Sciences Business Overview
10.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.22.4 Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.22.5 Caris Life Sciences Recent Development
13.23 Myriad Genetics
10.23.1 Myriad Genetics Company Details
10.23.2 Myriad Genetics Business Overview
10.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.23.4 Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.23.5 Myriad Genetics Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Clinical Oncology Next Generation Sequencing (NGS) Revenue
1.4 Market by Type
1.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 NGS Pre-Sequencing
1.4.3 Sequencing
1.4.4 NGS Data Analysis
1.4.5 Primary, Secondary & Tertiary Data Analysis
1.5 Market by Application
1.5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application: 2020 VS 2026
1.5.2 Academic & Clinical Research
1.5.3 Hospitals & Clinics
1.5.4 Pharma & Biotech Entities
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Perspective (2015-2026)
2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Growth Trends by Regions
2.2.1 Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Historic Market Share by Regions (2015-2020)
2.2.3 Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Clinical Oncology Next Generation Sequencing (NGS) Market Growth Strategy
2.3.6 Primary Interviews with Key Clinical Oncology Next Generation Sequencing (NGS) Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Market Size
3.1.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue (2015-2020)
3.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Players (2015-2020)
3.1.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio
3.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2019
3.3 Clinical Oncology Next Generation Sequencing (NGS) Key Players Head office and Area Served
3.4 Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
3.5 Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Type (2015-2020)
4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
6.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in North America (2019-2020)
6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
6.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
7 Europe
7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
7.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Europe (2019-2020)
7.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
7.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
8 China
8.1 China Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
8.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in China (2019-2020)
8.3 China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
8.4 China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
9 Japan
9.1 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
9.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Japan (2019-2020)
9.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
9.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
10.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
10.4 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
11 India
11.1 India Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
11.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in India (2019-2020)
11.3 India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
11.4 India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
12.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Central & South America (2019-2020)
12.3 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
12.4 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Illumina
13.1.1 Illumina Company Details
13.1.2 Illumina Business Overview
13.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.1.4 Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020))
13.1.5 Illumina Recent Development
13.2 Roche
13.2.1 Roche Company Details
13.2.2 Roche Business Overview
13.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.2.4 Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.2.5 Roche Recent Development
13.3 Agilent Technologies
13.3.1 Agilent Technologies Company Details
13.3.2 Agilent Technologies Business Overview
13.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.3.4 Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.3.5 Agilent Technologies Recent Development
13.4 Knome
13.4.1 Knome Company Details
13.4.2 Knome Business Overview
13.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.4.4 Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.4.5 Knome Recent Development
13.5 Genomatix Software
13.5.1 Genomatix Software Company Details
13.5.2 Genomatix Software Business Overview
13.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.5.4 Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.5.5 Genomatix Software Recent Development
13.6 GATC Biotech
13.6.1 GATC Biotech Company Details
13.6.2 GATC Biotech Business Overview
13.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.6.4 GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.6.5 GATC Biotech Recent Development
13.7 Oxford Nanopore Technologies
13.7.1 Oxford Nanopore Technologies Company Details
13.7.2 Oxford Nanopore Technologies Business Overview
13.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.7.4 Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.7.5 Oxford Nanopore Technologies Recent Development
13.8 Macrogen
13.8.1 Macrogen Company Details
13.8.2 Macrogen Business Overview
13.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.8.4 Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.8.5 Macrogen Recent Development
13.9 Life Technologies
13.9.1 Life Technologies Company Details
13.9.2 Life Technologies Business Overview
13.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.9.4 Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.9.5 Life Technologies Recent Development
13.10 DNASTAR
13.10.1 DNASTAR Company Details
13.10.2 DNASTAR Business Overview
13.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.10.4 DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.10.5 DNASTAR Recent Development
13.11 Exosome Diagnostics
10.11.1 Exosome Diagnostics Company Details
10.11.2 Exosome Diagnostics Business Overview
10.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.11.4 Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.11.5 Exosome Diagnostics Recent Development
13.12 Biomatters
10.12.1 Biomatters Company Details
10.12.2 Biomatters Business Overview
10.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.12.4 Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.12.5 Biomatters Recent Development
13.13 CLC Bio
10.13.1 CLC Bio Company Details
10.13.2 CLC Bio Business Overview
10.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.13.4 CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.13.5 CLC Bio Recent Development
13.14 BGI
10.14.1 BGI Company Details
10.14.2 BGI Business Overview
10.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.14.4 BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.14.5 BGI Recent Development
13.15 Qiagen
10.15.1 Qiagen Company Details
10.15.2 Qiagen Business Overview
10.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.15.4 Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.15.5 Qiagen Recent Development
13.16 Perkin Elmer
10.16.1 Perkin Elmer Company Details
10.16.2 Perkin Elmer Business Overview
10.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.16.4 Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.16.5 Perkin Elmer Recent Development
13.17 Pacific Bioscience
10.17.1 Pacific Bioscience Company Details
10.17.2 Pacific Bioscience Business Overview
10.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.17.4 Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.17.5 Pacific Bioscience Recent Development
13.18 Partek
10.18.1 Partek Company Details
10.18.2 Partek Business Overview
10.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.18.4 Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.18.5 Partek Recent Development
13.19 GnuBIO
10.19.1 GnuBIO Company Details
10.19.2 GnuBIO Business Overview
10.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.19.4 GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.19.5 GnuBIO Recent Development
13.20 Foundation Medicine
10.20.1 Foundation Medicine Company Details
10.20.2 Foundation Medicine Business Overview
10.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.20.4 Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.20.5 Foundation Medicine Recent Development
13.21 Paradigm
10.21.1 Paradigm Company Details
10.21.2 Paradigm Business Overview
10.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.21.4 Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.21.5 Paradigm Recent Development
13.22 Caris Life Sciences
10.22.1 Caris Life Sciences Company Details
10.22.2 Caris Life Sciences Business Overview
10.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.22.4 Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.22.5 Caris Life Sciences Recent Development
13.23 Myriad Genetics
10.23.1 Myriad Genetics Company Details
10.23.2 Myriad Genetics Business Overview
10.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.23.4 Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.23.5 Myriad Genetics Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
